Spine SurgeryEngagement Letter
InsightsOutcomes Literature

Stem Cell Therapy in Spine Care: What the Medical Literature Reports on Fusion, Disc Degeneration, and Spinal Cord Injury

An educational overview of what systematic reviews, randomized trials, early-phase studies, and regulatory sources report about cell-based therapies in spine care.

Stem cell therapy is one of the most widely discussed and most widely marketed topics in spine care. The phrase is used for very different things: cell-containing bone graft products placed during fusion surgery, investigational injections into degenerated discs, early-phase transplantation studies for spinal cord injury, and injections sold directly to consumers. This article summarizes what systematic reviews, randomized trials, early-phase clinical studies, and regulatory sources report for each of these uses. It is intended as an educational overview.

What "stem cell therapy" means in spine care

Most spine applications use mesenchymal stromal or stem cells (MSCs), which can be obtained from bone marrow, fat, umbilical tissue, or donor bone. Laboratory studies describe these cells as capable of supporting bone or cartilage-like tissue and of releasing signaling molecules that influence inflammation and healing. Other approaches use cells derived from disc tissue or neural progenitor cells grown from induced pluripotent stem cells (iPSCs). These biologic differences matter because results from one cell type, dose, source, or delivery method are not automatically transferable to another.

Products also differ in how they are prepared. Some are minimally processed, such as bone marrow aspirate concentrate prepared at the point of care. Others are culture-expanded in a laboratory to a defined cell count, or are allogeneic donor products manufactured at scale. Reviews consistently note that marketing language often does not distinguish among these categories, and that cell counts and viability are frequently not reported for commercially available preparations.

Interactive evidence map

Where the cell-therapy evidence stands in spine care

Select an application to view the strongest published evidence, what it reports, its main limitations, and current regulatory status.

Application

Evidence maturity

Comparative cohorts; no published RCTs

Strongest published evidence
Systematic reviews of roughly 19–22 studies, mostly retrospective case series and small nonrandomized comparisons.
What studies report
High fusion rates are reported (about 82–100% lumbar, 87–100% cervical), but comparative studies have not shown superiority over cell-free allograft, demineralized bone matrix, autograft, or rhBMP-2.
Main limitations
Heterogeneous fusion criteria, industry-linked authorship in many studies, higher cost than cell-free grafts, and two U.S. tuberculosis outbreaks linked to single donor lots of viable bone matrix.
Regulatory status
Marketed in the U.S. as tissue-based allografts; graft selection remains a surgeon-level decision.

The maturity bar is a simplified editorial summary of study design and volume, not a formal evidence grade or a measure of benefit.

Educational. Not a diagnostic or treatment tool.

Cellular bone grafts in spinal fusion

The most established clinical use is in spinal fusion, where cellular bone allografts, also called cellular bone matrices, are used as graft extenders. These products combine donor bone scaffold with viable cells and are intended to add osteogenic potential similar to a patient's own bone graft without the morbidity of harvesting it. Their use expanded rapidly during the past decade.

Systematic reviews describe high reported fusion rates. A 2024 review in Global Spine Journal identified 19 studies of seven products and reported lumbar fusion rates of 68% to 98.7% and cervical rates of 87% to 100%. A 2026 review in Neurosurgical Practice identified 22 studies, reporting lumbar rates of 82% to 100% and cervical rates of 90% to 98.5%. Both reviews found that no study demonstrated a statistically significant improvement in fusion over cell-free allograft, demineralized bone matrix, autograft, or rhBMP-2. An earlier 2019 review graded the evidence as very low certainty.

These reviews also identify recurring limitations. Most studies were retrospective case series or small nonrandomized comparisons, and no randomized controlled trials had been published. Fusion was assessed with different imaging methods and definitions. The 2024 review reported that authors of 14 of 19 studies had financial relationships with the product's manufacturer or distributor, and that those studies reported lower complication rates than studies without such relationships. Cost data were limited and institution-specific, generally placing cellular allografts above cell-free grafts but below rhBMP-2.

Safety discussions focus on donor screening. Because viable-cell products cannot undergo terminal sterilization without destroying the cells, two U.S. tuberculosis outbreaks have been traced to single donor lots of viable bone matrix. The 2021 outbreak exposed 87 recipients and resulted in eight deaths, and a 2023 outbreak involved up to 36 patients and two deaths. Reviews describe these events as rare but serious, and call for standardized donor testing and postmarket surveillance.

Intradiscal cell therapy for degenerative disc disease

The second major application is injection of cells into a degenerated disc to address chronic low back pain thought to arise from the disc. The rationale is that the disc has limited capacity for self-repair, and that added cells may reduce inflammation or support matrix production. This area has the largest body of randomized evidence among spine cell therapies, and its results are mixed.

A 2025 systematic review in Neurospine identified 10 published clinical studies with 736 participants, including five randomized controlled trials. Pain and disability generally improved after treatment, but the authors described the improvements as modest and noted that controlled trials often did not show a statistically significant advantage over control injections. Imaging changes in disc hydration or height were reported in some studies and not others. The review concluded that the therapy has biological plausibility and preliminary safety data but remains largely experimental.

Key randomized trials

  • RESPINE (2024, Annals of the Rheumatic Diseases): 114 patients randomized to 20 million allogeneic bone marrow MSCs or a sham procedure. At 12 months, 74% of the cell group and about 69% of the sham group met the responder definition, and the co-primary clinical and MRI endpoints were not met. The procedure was reported as safe, with no disc infections.
  • Mesoblast rexlemestrocel-L phase 3 (404 patients): the prespecified composite primary endpoint of pain and function at 12 and 24 months was not met in the full population. Pain reduction was greater than control at 12 and 24 months for cells combined with a hyaluronic acid carrier, with larger effects in a prespecified subgroup with shorter symptom duration.
  • DiscGenics phase 1/2 (60 patients): the high-dose disc progenitor cell group met its pain-reduction endpoint and showed increased disc volume on MRI, while between-group differences in pain change were not statistically significant. The trial was sponsor-funded, and the authors identified its small size as a limitation.

These trials illustrate a consistent challenge: patients in control groups improve substantially, so apparent benefit in uncontrolled case series can overstate the effect attributable to the cells. Confirmatory phase 3 programs are now underway. Mesoblast reports completing treatment of 350 patients in a second phase 3 trial focused on patients with symptoms of less than five years, with topline results expected in mid-2027, and DiscGenics began treating patients in its phase 3 program in January 2026. Until those results are published, no intradiscal cell therapy is approved in the United States.

Point-of-care bone marrow aspirate concentrate is a separate category. Systematic reviews of intradiscal bone marrow concentrate report favorable changes in uncontrolled series, but comparative data are limited and the composition of these preparations varies widely between patients and processing systems. Payer medical policies generally continue to classify intradiscal cell and allograft injections as investigational.

Cell therapy for spinal cord injury

Spinal cord injury research addresses a different goal: restoring neural function rather than supporting bone or disc tissue. Studies to date are small and early-phase. The Mayo Clinic CELLTOP phase 1 trial, published in Nature Communications in 2024, gave intrathecal fat-derived MSCs to 10 patients with AIS A or B injuries about 11 months after injury. No serious adverse events were reported, and seven participants improved by at least one AIS grade over two years. The investigators emphasized that the study was not designed to establish efficacy and called for larger controlled trials.

In Japan, Keio University reported in 2026 on the first clinical study of iPSC-derived neural progenitor cells for subacute complete spinal cord injury. In four patients followed for up to four years, no tumor formation or serious treatment-related adverse events were observed, and motor improvements at one year exceeded those of a historical control cohort. Separately, Japan granted conditional, time-limited approval to Stemirac, an autologous bone marrow MSC product, in 2018 based on a 13-patient single-arm study; a ministry panel endorsed full approval in October 2026 after post-marketing surveillance. Commentators have noted that spontaneous neurologic recovery after injury, particularly incomplete injury, makes uncontrolled results difficult to interpret.

Across spine applications, cell-based therapies show encouraging safety data and biological rationale, while controlled evidence of clinical benefit over established alternatives remains limited or unconfirmed.

Regulation and direct-to-consumer marketing

In the United States, the FDA regulates cell-based products according to how they are processed and used. Minimally manipulated tissues intended for the same basic function, such as many bone allografts, can be marketed under tissue regulations, while culture-expanded or more-than-minimally manipulated cells generally require clinical trials and approval as biologic drugs. FDA consumer guidance states that the only approved stem cell products are cord blood-derived blood-forming cells for blood disorders, and that no regenerative medicine therapy is approved for orthopedic conditions or chronic pain.

The FDA has issued repeated warning letters to clinics and manufacturers marketing umbilical, amniotic, fat-derived, and exosome products outside clinical trials, and has described reports of infection, tumor formation, and other harms associated with unapproved products. The agency notes that a listing on ClinicalTrials.gov or a firm's registration with FDA does not mean a product is approved. Similar concerns have been described internationally; a 2026 study identified 41 non-research spinal cord injury cell therapy plans in Japan with marked variation in cell source, dose, and route.

Summary of the published evidence

Across systematic reviews, randomized trials, and early-phase studies, several themes recur. Cellular bone grafts used in fusion are associated with high fusion rates, but comparative studies have not shown them to outperform conventional graft options, and the evidence base is largely retrospective. Intradiscal cell therapy has produced mixed randomized results, with substantial improvement in control groups and confirmatory phase 3 trials still in progress. Spinal cord injury studies report acceptable early safety and some functional gains in small samples, but lack the controlled designs needed to establish benefit. Products marketed directly to consumers generally fall outside this evidence base. The field is active, and conclusions may change as larger trials report.

This overview is educational. It is not medical advice, does not evaluate any specific patient or matter, and does not substitute for review of the primary peer-reviewed sources.

Frequently asked

Common questions on this topic

Are any stem cell therapies FDA-approved for back pain or spine conditions?

FDA consumer guidance states that no regenerative medicine therapy is approved for orthopedic conditions or chronic pain. Several intradiscal cell products are being studied in FDA-overseen phase 3 trials. Cellular bone allografts used in fusion surgery are marketed as tissue products rather than approved as drugs.

Do cellular bone grafts improve spinal fusion rates?

Systematic reviews report high fusion rates with cellular bone allografts, but comparative studies have not shown statistically significant improvement over cell-free allograft, demineralized bone matrix, autograft, or rhBMP-2. Most studies are retrospective, and no randomized trials had been published as of the 2026 review.

What did randomized trials of intradiscal stem cell injection find?

Results are mixed. The 114-patient RESPINE trial did not meet its primary endpoints, and a 404-patient phase 3 trial missed its composite primary endpoint while reporting pain reduction in some analyses. Control groups improved substantially in several trials, and confirmatory phase 3 trials are ongoing.

Can stem cells restore function after spinal cord injury?

Early-phase studies report acceptable short-term safety and some improvement in neurologic grade in small groups of patients. These studies were not designed to prove efficacy, and natural recovery after injury complicates interpretation. Japan has approved one product, Stemirac, while no such therapy is FDA-approved.

Why is evidence from clinic-marketed stem cell injections difficult to evaluate?

Clinic-marketed products vary in source, processing, cell count, and viability, and are often not documented. Outcome reports are frequently uncontrolled. The FDA has warned that many such products are marketed without required clinical-trial oversight and has described reports of serious harms.

About this article

This article is an educational summary of the peer-reviewed medical literature and current clinical practice on the topic addressed. It is written by Ahmer K. Ghori, MD, a board-certified orthopedic spine surgeon. It is not medical advice, does not evaluate any specific patient or matter, and does not substitute for review of the primary sources.

More educational articles are available on the Insights index.